Float Near Exhaustion as Institutional Ownership Tops 102% at Intellia Therapeutics

Strong accumulation flow and bullish options positioning signal heightened conviction despite a constrained share supply

NTLA Intellia Therapeutics, Inc.

In this report

01

Institutional Ownership

Quarterly ownership trends, direction, investor count

→

02

Position Flow Analysis

Flow ratio, conviction, new vs closed positions

→

03

Float & Options Context

Put/call ratio, free float estimate, hedging activity

→

04

Insider Trading Patterns

Insider buys/sells, top transactions, cluster buying, post-buy returns

→

05

Smart Money Summary

Convergence/divergence flags, key takeaways

→

Institutional Ownership Trends

Intellia Therapeutics, Inc. (NTLA) — Ownership Profile

Institutional ownership of Intellia Therapeutics (NTLA) stands at an unusually high 101.89%, indicating the stock is heavily institutionalized and that a substantial portion of the float is held by large investors, which can limit free‑float liquidity. Ownership increased by 4.02 percentage points in the most recent quarter, reflecting a short‑term accumulation trend, although the two‑quarter streak falls just short of the three‑quarter threshold required to label the pattern as sustained accumulation. The investor base expanded to 319 institutional holders, suggesting growing interest despite the already high concentration.

Ownership Overview

NTLA

The company is experiencing a modest upward shift in institutional ownership, with a 4.02pp quarterly gain and a two‑quarter consecutive increase that points to ongoing accumulation but not yet a sustained trend. The exceptionally high ownership level (>90%) underscores heavy institutional control, which may constrain float and amplify price movements on large trades. Nonetheless, the rise in the number of institutional investors to 319 signals broadened participation and could support future liquidity.

Position Flow Analysis

Intellia Therapeutics, Inc. (NTLA) — Position Flows

Intellia Therapeutics (NTLA) exhibits strong net accumulation, reflected by a current flow ratio of 2.2, well above the 1.5 threshold that signals aggressive buying pressure. The conviction ratio of 0.75 indicates that existing shareholders are not only holding but also adding to their positions, reinforcing the bullish sentiment from both new and incumbent investors.

Position Flow Metrics

NTLA

The flow ratio of 2.2 suggests institutions are opening fresh positions at a significant pace, while the conviction ratio of 0.75 shows that current holders are increasing their stakes. Combined with a net inflow of 138 units, the data points to robust demand and confidence in the company's near‑term outlook.

Float & Options Context

Intellia Therapeutics, Inc. (NTLA) — Float & Options

Intellia Therapeutics (NTLA) exhibits a heavily call‑biased options market, with a put/call ratio of 0.37 well below the 0.5 threshold that signals aggressive buying of calls relative to puts. This pattern suggests that option traders—often institutional participants—are positioning for upside rather than hedging against downside risk. At the same time, the estimated free float is -1.89%, derived from an institutional ownership level of 101.89%; a negative float indicates that virtually all publicly tradable shares are already held by institutions or other locked‑in parties, creating a severely constrained supply environment that could amplify price moves in either direction.

Float & Options Overview

NTLA

The call‑heavy options positioning reflects bullish sentiment among traders, reinforcing the view that investors anticipate upside potential. However, the effectively negative free float signals a constrained share pool, which can limit liquidity and increase volatility, especially if any large holder decides to sell. The convergence of strong bullish options bets with a tightly held float raises both upside upside potential and squeeze‑related risk for the stock.

Float & Options Context

Intellia Therapeutics, Inc. (NTLA) — Put/Call Ratio

Insider Trading Patterns

Intellia Therapeutics, Inc. (NTLA) — Insider Activity

Over the past 12 months, insiders at Intellia Therapeutics executed 24 transactions totaling $4.27 million, with purchases amounting to $2.41 million (2 buys) and sales $1.87 million (22 sells). The resulting buy‑sell value ratio of 1.29 indicates a modest net buying bias, well below the 2.0 threshold that would signal strong insider confidence, while the count ratio of 0.09 reflects far more selling events than purchases. Notably, two director purchases—Fred E. Cohen ($1.40 M) and William J. Chase ($1.00 M)—account for virtually all buying activity, and both were followed by a 30‑day post‑buy return of 42.3%, yielding a perfect 100% success rate for buys exceeding $100 K.

Insider Activity Summary

NTLA

Insider activity shows limited buying concentrated among directors, with no evidence of coordinated cluster purchases (fewer than three insiders buying within a 30‑day window). The high post‑buy success rate suggests recent buys were well‑timed, but the overall modest buy‑sell ratio and predominance of routine sales—particularly from CEO John M. Leonard—temper any bullish interpretation.

Insider Trading Patterns

Intellia Therapeutics, Inc. (NTLA) — Insider Timeline

Smart Money Summary

Intellia Therapeutics, Inc. (NTLA) — Summary & Implications

Intellia Therapeutics (NTLA) exhibits a pronounced concentration of institutional ownership, now exceeding 100% of the float at 101.89%, reflecting significant share borrowing and re‑lending activity that has driven the effective ownership above the total outstanding shares. Over the last quarter the institutionally held portion rose by 4.02 percentage points, indicating strong net accumulation as captured by a flow class of "strong accumulation" and a flow ratio of 0.75, well above the 0.5 threshold for meaningful buying pressure. Insider activity aligns with this institutional trend, showing a net insider buying ratio of 1.29 and a purchase‑to‑sale (P/C) ratio of 0.37, suggesting insiders are acquiring shares at a modest pace relative to their sales, reinforcing the positive sentiment from smart money participants.

Smart Money Dashboard

Key Takeaways

Institutional ownership exceeds 100% of the float, indicating heavy share borrowing and a tightly held supply.
A 4‑percentage‑point increase in institutional holdings over one quarter underscores aggressive net buying by smart money.
Insider buying outpaces insider selling (ratio 1.29), providing corroborating bullish sentiment from company insiders.
The convergence of institutional accumulation and insider purchases strengthens the overall positive positioning despite potential float constraints.
High ownership concentration may limit additional large‑scale inflows, but current smart‑money activity suggests confidence in upcoming catalysts.

NTLA

The convergence of robust institutional accumulation and insider buying signals a coordinated confidence in NTLA's near‑term prospects, despite the constrained float that could amplify price volatility. While high ownership levels may limit further inflows from large institutions, the current positioning reflects strong conviction among existing shareholders.

NTLA

Related Reports

Explore more at Finexus Reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.